JP2014534956A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534956A5
JP2014534956A5 JP2014533950A JP2014533950A JP2014534956A5 JP 2014534956 A5 JP2014534956 A5 JP 2014534956A5 JP 2014533950 A JP2014533950 A JP 2014533950A JP 2014533950 A JP2014533950 A JP 2014533950A JP 2014534956 A5 JP2014534956 A5 JP 2014534956A5
Authority
JP
Japan
Prior art keywords
seq
composition
use according
patient
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014533950A
Other languages
English (en)
Japanese (ja)
Other versions
JP6239517B2 (ja
JP2014534956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/070074 external-priority patent/WO2013053767A1/en
Publication of JP2014534956A publication Critical patent/JP2014534956A/ja
Publication of JP2014534956A5 publication Critical patent/JP2014534956A5/ja
Application granted granted Critical
Publication of JP6239517B2 publication Critical patent/JP6239517B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014533950A 2011-10-10 2012-10-10 関節リウマチの治療法 Expired - Fee Related JP6239517B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161545359P 2011-10-10 2011-10-10
US61/545,359 2011-10-10
US201161556974P 2011-11-08 2011-11-08
US61/556,974 2011-11-08
PCT/EP2012/070074 WO2013053767A1 (en) 2011-10-10 2012-10-10 Treatment for rheumatoid arthritis

Publications (3)

Publication Number Publication Date
JP2014534956A JP2014534956A (ja) 2014-12-25
JP2014534956A5 true JP2014534956A5 (enExample) 2015-11-26
JP6239517B2 JP6239517B2 (ja) 2017-11-29

Family

ID=47010599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533950A Expired - Fee Related JP6239517B2 (ja) 2011-10-10 2012-10-10 関節リウマチの治療法

Country Status (9)

Country Link
US (1) US20140335081A1 (enExample)
EP (1) EP2766394B1 (enExample)
JP (1) JP6239517B2 (enExample)
CN (1) CN103906767A (enExample)
AU (2) AU2012322991B2 (enExample)
CA (1) CA2851322C (enExample)
ES (1) ES2660776T3 (enExample)
RU (1) RU2014117510A (enExample)
WO (1) WO2013053767A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2714919C2 (ru) * 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
AU2015263285A1 (en) * 2014-05-19 2016-11-24 Medimmune Limited Treatment for rheumatoid arthritis
WO2017202879A1 (en) 2016-05-24 2017-11-30 Medimmune Limited Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
WO2018144334A1 (en) * 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
US20220010007A1 (en) 2018-11-09 2022-01-13 Kiniksa Pharmaeuticals, Ltd. Treatment for Giant Cell Arteritis
CN111868073B (zh) * 2019-05-31 2021-04-30 广州市雷德生物科技有限公司 一种类风湿关节炎相关的特异性多肽及其应用
CN114599398A (zh) 2019-06-03 2022-06-07 基尼克萨制药有限公司 用gm-csf拮抗剂治疗癌症
WO2021188409A1 (en) 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
KR20230095983A (ko) 2020-10-26 2023-06-29 키닉사 파마슈티컬스, 리미티드 Gm-csf 길항제를 사용한 암의 치료
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
KR101481844B1 (ko) * 2006-03-27 2015-01-13 메디뮨 리미티드 Gm-csf 수용체에 대한 결합 성분
PT2049123E (pt) * 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
JP2013518590A (ja) * 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド TNF−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Similar Documents

Publication Publication Date Title
AU2020223706B2 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
JP7434456B2 (ja) 抗il-13抗体を使用する、il-13活性が有害である疾患の治療方法
JP6526037B2 (ja) Il−4rアンタゴニストを投与することによる皮膚感染を処置するための方法
JP6877357B2 (ja) Gdf8阻害剤を用いて、強度及び機能を増加させる方法
JP2006522830A5 (enExample)
RU2014117510A (ru) Лечение ревматоидного артрита
JP2021523188A (ja) Il−4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
RS58091B1 (sr) Metode za tretiranje ili prevenciju astme davanjem antagonista il-4r
KR20150048887A (ko) Il-4r 길항제 투여로 아토피성 피부염을 치료하는 방법
KR20220035272A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
JP2011506483A5 (enExample)
AU2022200690B2 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
JP2026062653A (ja) シェーグレン症候群の処置
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
CA3164126A1 (en) Antibodies for the treatment of chronic graft versus host disease
KR20250011948A (ko) 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법
JP2024517796A (ja) 抗baffr抗体を使用するループス腎炎の治療
JP2002521491A (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのcd25結合分子
WO2025257781A1 (en) Treatment of systemic sclerosis using anti-baff-r antibodies
TW202434632A (zh) 治療重症肌無力之方法
JP2024516019A (ja) 抗baffr抗体を使用する全身性エリテマトーデスのための治療
WO2025120567A1 (en) Method of treatment of asthma
HK1225635A1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
HK1225635B (en) Compositions for the treatment of rheumatoid arthritis and methods of using same